Trial Profile
A Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of BYM338 in Patients With Sporadic Inclusion Body Myositis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Mar 2017
Price :
$35
*
At a glance
- Drugs Bimagrumab (Primary)
- Indications Inclusion body myositis
- Focus Proof of concept; Therapeutic Use
- Sponsors Novartis
- 13 Jun 2015 Results presented at the 16th Annual Congress of the European League Against Rheumatism.
- 30 Sep 2014 New trial record